PHARMACEUTICALS related term(s) Drugs

Amendments

Agriculture, rural development, FDA, and related agencies programs: authorizing appropriations (H.R. 1976), H6736 [10JY], H6831 [11JY]

Articles and editorials

Alzheimer's Patients Need FDA Reform, E1932 [12OC]

Battle Over Bonanza for Drug Companies, S15426 [23OC]

Costly Oversight—Fine Print in GATT Law Could Cost Zantac Users Millions, S18202 [7DE]

Drug Company Preserves Tax Break in Senate Committee, S15425 [23OC]

Drug Firms at Odds Over Patent Extension, S15427 [23OC]

Drug Firms Fight To Preserve Windfall, S15425 [23OC]

Drugs Get Extra Patent Time, S15424 [23OC]

Four Drug Firms Could Gain $1 Billion Under GOP Nutrition-Program Revision, S5163 [5AP]

GATT Delayed New Generic Drugs, S15429 [23OC]

GATT Puts Generic Drugs on Hold, S15429 [23OC]

Generic-Drug Talks Stall in Committee, S15425 [23OC]

Patient Medicine Called GATT—For Makers of Branded Drugs, It Could Prove a Powerful Tonic, S6495 [11MY]

Ruling Shortens Branded Drugs' Monopoly, S15430 [23OC]

Senate Panel—No Vote on Drug Loophole, S15426 [23OC]

Senator From Glaxo?, S15426 [23OC]

Simpson Abstains Because of Stock, S15424 [23OC]

Three Drug Makers Win Suit To Extend Protection of Patents, S15422 [23OC]

Zantac Windfall, S18203 [7DE], E2436 [21DE]

Bills and resolutions

Agriculture, rural development, FDA, and related agencies programs: authorizing appropriations (see H.R. 1976), H6697 [30JN]

Business and industry: provide equitable relief for the generic drug industry (see S. 1277), S14408 [27SE]

Diseases: establish temporary program allowing the use of parenteral diacetylmorphine for intractable pain due to cancer (see S. 78), S49 [4JA]

———prostate cancer screening and drug treatments and expansion of research and education programs (see S. 691), S5403 [6AP]

Drugs: revise drug approval process (see H.R. 1742), H5622 [6JN]

Health: accessibility of alternative treatments and medicines (see S. 1035; H.R. 2019), S9998 [14JY], H6913 [12JY]

Medicare: prostate cancer screening (see H.R. 1496), H4431 [7AP]

Patents: extend protection for nonsteroidal anti-inflammatory drugs (see S. 1496), S19110 [21DE]

Tariff: pharmaceutical-grade phospholipids (see S. 1015), S9638 [10JY]

Taxation: credit for clinical testing expenses for certain drugs for rare diseases or conditions (see S. 1052), S10426 [20JY]

Letters

GATT implementation relative to generic drugs: Abbey S. Meyers, National Organization for Rare Disorders, Inc., S6496 [11MY]

———Bill Magruder, Premier Health Alliance, Inc., S6496 [11MY]

———C. Everett Koop, S18104 [6DE], S18209, S18211 [7DE]

———Christine Sizemore, National Pharmaceutical Alliance, S6497 [11MY]

———Clayton Yeutter, S18213 [7DE]

———Daniel Perry, Alliance for Aging Research, S18206 [7DE]

———Dixie Horning, Gray Panthers Project Fund (organization), S6496 [11MY]

———Eugene P. Schonfeld, National Kidney Association, S18205 [7DE]

———Joseph W. Mulroy, AmeriVet (organization), S6496 [11MY]

———Judith G. Waxman, Families USA Foundation, S6496 [11MY]

———Judith Simpson, United Patients' Association for Pulmonary Hypertension, Inc., S18205, S18212 [7DE]

———Leon Brittan, European Commission, S18213 [7DE]

———Patti Munter, National Organization on Fetal Alcohol Syndrome, S18205 [7DE]

———Robert J. Beall, Cystic Fibrosis Foundation, S18205 [7DE]

———Ronald L. Ziegler, National Association of Chain Drug Stores, S6497 [11MY]

———Senators Dodd and Hatch, S18211 [7DE]

———several Senators, S18210 [7DE]

———William Brock, S18213 [7DE]

Pharmaceutical patent extension: Cynthia Pearson, National Women's Health Network, S15430 [23OC]

———Edmund Mierzwinski, U.S. Public Interest Research Group, S15431 [23OC]

———Esther Peterson and Edmund H. Worthy, Jr., United Seniors Health Cooperative, S15431 [23OC]

———James Firman, Generic Drug Equity Coalition, S15430 [23OC]

———James Firman, National Council on the Aging, Inc., S15430 [23OC]

———James P. Love, Consumer Project on Technology, S15432 [23OC]

———Jordan Clark, United Homeowners Association, S15432 [23OC]

———Karen Fennell, American College of Nurse-Midwives, S15431 [23OC]

———Kim Youngblood, National Black Women's Health Project (organization), S15431 [23OC]

———Martha A. McSteen, National Committee To Preserve Social Security and Medicare, S15431 [23OC]

———Max Starkloff, Paraquad Inc., S15432 [23OC]

———Mern Horan, Consumer Federation of America, Gene Kimmelman, Consumers Union, and Cathy Hurwit, Citizen Action (organization), S15430 [23OC]

———Michael Calabrese, Public Citizen (organization), S15431 [23OC]

———Michael Kantor, U.S. Trade Representative, S15423 [23OC]

———Richard Fitzpatrick, National Coalition for Homeless Veterans, S15432 [23OC]

Remarks in House

Drugs: revise drug approval process, H5686 [7JN], E1273 [16JN], E1932 [12OC]

———revise drug approval process (H.R. 1742), E1157 [6JN]

Endangered species: protection of rare plants, animals, and organisms used for medical purposes, H3094 [14MR], H3158 [15MR], H3338 [21MR], H3421 [22MR], H3577 [23MR], H3737 [24MR]

Federal-State relations: exempt child immunization programs from unfunded Federal mandates reform, H937, H938 [31JA]

Health: accessibility of alternative treatments and medicines (H.R. 2019), E1424 [12JY]

Medicare: prostate cancer screening (H.R. 1496), H4339 [6AP]

NIH: pharmaceutical research funding, H8408-H8410 [3AU]

Safety: improving child-proof medicine caps, H6048 [16JN]

Remarks in Senate

Business and industry: generic drug competition in the prescription drug marketplace, S5180-S5182 [5AP]

Dept. of Defense: conduct mail service pharmacy demonstration projects, S4059 [16MR]

Diseases: development of a vaccine preventing a recurrence of breast cancer, S2529 [10FE]

———establish temporary program allowing the use of parenteral diacetylmorphine for intractable pain due to cancer (S. 78), S290 [4JA]

———prostate cancer screening and drug treatments and expansion of research and education programs (S. 691), S5426 [6AP]

Drugs: ensure availability of generic drugs (S. 1191), S15421 [23OC], S16593 [2NO]

Foreign trade: expand authority for the export of pharmacological and biological products, and medical devices, S10748, S10749, S10751 [27JY]

GATT: implementation relative to generic drugs, S6494 [11MY], S15421 [23OC], S16593 [2NO], S18004 [5DE], S18199-S18222 [7DE]

Health: accessibility of alternative treatments and medicines (S. 1035), S9999-S10002 [14JY]

Kalamazoo, MI: pretreatment requirements for a pharmaceutical plant, S14364, S14365 [27SE]

Patents: extend protection for nonsteroidal anti-inflammatory drugs (S. 1496), S19117 [21DE]

Tariff: pharmaceutical-grade phospholipids (S. 1015), S9638 [10JY]

Taxation: credit for clinical testing expenses for certain drugs for rare diseases or conditions (S. 1052), S10426 [20JY]

WIC: designate funds to promote immunization, S5322 [6AP]

Reports filed

Agriculture, Rural Development, FDA, and Related Agencies Programs Appropriations: Committee on Appropriations (House) (H.R. 1976) (H. Rept. 104-172), H6697 [30JN]

Summaries

Economic Impact of GATT Patent Extension on Currently Marketed Drugs: University of Minnesota College of Pharmacy, S15424 [23OC]

Testimonies

Role of Pharmaceutical Companies in Health Care Reform: Gerald J. Mossinghoff, Pharmaceutical Manufacturers Association, S6063 [3MY]

Texts of

S. 78, Compassionate Pain Relief Act, S291 [4JA]

S. 1015, tariffs on phamaceutical-grade phospholipids, S9638 [10JY]

S. 1035, Access to Medical Treatment Act, S10000 [14JY]

S. 1052, tax credit for clinical testing expenses for certain drugs for rare diseases or conditions, S10427 [20JY]

Transcripts

Pharmaceutical Patent Extension: Lisa Meyers, NBC Nightly News, S15426 [23OC]